Arboleya Luis, Alperi Mercedes, Alonso Sara
Servicio de Reumatología, Hospital Universitario Central de Asturias, Oviedo, España.
Reumatol Clin. 2011 May-Jun;7(3):189-97. doi: 10.1016/j.reuma.2010.10.005. Epub 2011 Mar 3.
Aminobisphosphonates are drugs that have been used successfully in the treatment of osteoporosis for more than 20 years. Although main registry studies found a scarcity of relevant adverse events, in recent years and as a result of pharmacovigilance, different complications have been reported, some potentially serious. This has raised questions on the safety of these drugs, especially in high doses, like those used in oncology and long-term treatment, as needed in patients with osteoporosis. In this review, based on the analysis of relevant scientific evidence from clinical trials, case series, cohort studies and databases published to date, we summarize the clinical and epidemiological characteristics of the adverse effects of these drugs.
氨基双膦酸盐类药物已成功用于治疗骨质疏松症20多年。尽管主要登记研究发现相关不良事件较少,但近年来,由于药物警戒,已报告了不同的并发症,有些可能很严重。这引发了对这些药物安全性的质疑,尤其是高剂量使用时,如肿瘤学中使用的剂量以及骨质疏松症患者所需的长期治疗剂量。在本综述中,基于对迄今为止发表的临床试验、病例系列、队列研究和数据库中的相关科学证据的分析,我们总结了这些药物不良反应的临床和流行病学特征。